Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label Phase II Study to Evaluate the Efficacy and Safety of Multiple Doses of SGB-9768 in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT07796256 is registered in ClinicalTrials.gov with Suzhou Sanegene Bio Inc. as lead sponsor.

NCT NCT07796256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07796256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label Phase II Study to Evaluate the Efficacy and Safety of Multiple Doses of SGB-9768 in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Lead sponsor
Suzhou Sanegene Bio Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2027
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pnh - paroxysmal nocturnal hemoglobinuria